Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Link below: not much more to say here.. se ya at the finish line..
but(in all seriousness my sister and father passed away from cancer recently so my sanity is pretty much out to lunch with this subject..) but I do feel I will have chances to take my initial money (.37-.20) off the table in the future if I choose.. w/a profit. before any FDA decision
http://www.biopharmcatalyst.com/fda-calendar/
..I bet you like bossy.. you wanna date, don't you ? come on now let your super-selves be known... what's your sign ?
THAT'S IT ! All of you Go To Your Rooms.. it's past your bedtime !! some of you will be TOS'd in the morning. or put in jail.. I'm not sure what you get for several aka's ?
Ad clicks = $$$ -eom
Things are looking better !! (holding) eom
I agree: "This has swung up and down a couple of times since I've owned it. The downward movement was the result of artificial pressure in small volume. It's inevitably going to go back up at some point, maybe higher next time."
..and even with the CEO thing.. I read a few things and even talked some chit..(before buying) but still the price and S/S and the fact that this guy was under a group of people then and so I took a 50/50 that He out on his own and gonna make a clean attempt.. I paid .0029 and still see a double+ trade up and then walk away.. it may take some time.. and I have 2 other stocks going way up so.. maybe I'll avg down ?? .. but this ain't over yet.. it just started.. IMO
WOW you were here a couple weeks ago, superwoman or something and some other name.. yeah, I knew, but this post was proof.., well have a nice day :).. trade on...
http://investorshub.advfn.com/Traders-Rehab-21607/
..not bad.. FLP(sea) 52-Wk Range 0.0021 - 0.08 -
Days H/L 0.048 - 0.0582
I believe it was a private company, but with them in the fold many things can be done in-house for sunshine.. the parent company brought them in.. if I read this right.. only thing that worried me a little was the world rights.. to our product.. it looks like we have just US rights..(forgot about that, but it will still be a mover just in US..) but I may be wrong ??
// Honestly I took a small position in this only to avoid a inactivity fee in my account.. saw a real good bio trader talk about it and bout some.. that was at like 37 cents.. Ha! //
I just glanced AV was bought from france and they're now perfecting it.. and bringing it through the steps to market.. and I'm gambling, and that pretty much sums it up for me..
..most of the negative things said here in the past few weeks didn't phase me.. 'cause they're the regular hurdles and set backs that most companies go through.. it'll be awhile and I have other things on the front burner.. so I don't take things to serious here at this point) and the price drops are a chance to buy more..
Advanomics Corporation to acquire Garmen Laboratories Finance | Manufacturing | Measurement+Analysis | North America | Research
Advanomics Corporation, a subsidiary of Sunshine Biopharma, a Canadian pharmaceutical company focused on the development of cancer drugs for the treatment of various forms of cancer, is to acquire GMP laboratory Garmen Laboratories for an undisclosed sum.
Garmen, a privately held Canadian firm located in Montreal, employs 45 people and provides pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. With nearly 35 years of industry experience, the firm offers solutions to detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.
Garmen will also manufacture 1kg of Adva-27a, Sunshine Biopharma's flagship anticancer drug candidate in development for multidrug resistant cancers at its good manufacturing practices (GMP) lab in Montreal. Advanomics said the material will be used to complete the remaining studies required to file an Investigational New Drug Application with the US FDA and conduct the breast cancer Phase I clinical trial of Adva-27a at McGill University's Jewish General Hospital in Montreal.
The firm recently received $1.45m in research grants from the NSERC, NanoQuebec and Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a. 'We are extremely pleased with the acquisition of Garmen Laboratories as it puts us in a prime position to continue to advance our novel cancer drug,' said Steve Slilaty, CEO of Sunshine Biopharma. 'We are excited that our methodical business plan in the development of Adva-27a is coming to fruition.' _gaq.push(['_trackEvent', 'Sunshine Biopharma Inc (22400)', 'News', 'Advanomics Corporation to acquire Garmen Laboratories(90990) 36753502']); Companies Sunshine Biopharma Inc - See more at:
http://www.manufacturingchemist.com/news/article_page/Advanomics_Corporation_to_acquire_Garmen_Laboratories/90990#sthash.mOyQzJE4.dpuf
A week from now this could be a whole new ballgame.. .03-.05 people don't even know about this yet.. ;)
For some reason, I'm able to be unaffected, just p/u the last chunk 60k at a penny (a lot I have are 3+) but I guess I'm to distracted by my bio-tech holds.. got a lot more money and 50/50 risk going on there.. I'm not sure what's going on here (got my assumptions) but when Dave is ready to retire I believe we will all cash in with Him..
I believe you cashed in on some 1-7 run ups.. and yours is gravy in the freezer.. and you were also getting deep into other holdings..
:) -eom
U guys could lock this float easy. -eom
maybe you sold ? interesting post record, "we- work together" setting hold till prices.. mmmh God bless ya..
"Papi" ..that's Lolita talk.. ?? eom
There's no need to fear! Underdog is here!
when criminals in this world appear
and break the laws that they should fear
and frighten all who see or hear
the cry goes up both far and near
for Underdog! Underdog! Underdog! Underdog!
speed of lightning, roar of thunder
fighting all who rob or plunder
Underdog. Underdog!
when in this world the headlines read
of those whose hearts are filled with greed
who rob and steal from those who need
to right this wrong with blinding speed
goes Underdog! Underdog! Underdog! Underdog!
speed of lightning, roar of thunder
fighting all who rob or plunder
Underdog. Underdog!
..your boy Frank from WNTR makes our CEO look like a Saint..;)
..not yet, it's pretty low ;) eom
Your welcome -eom
...bless you -eom
a limit order - eom
?? I got an order to buy more. -eom
mmh - eom
..thanks -eom
I just grabbed 20900 at .0165 and it went through.. but didn't see it move up at all.. wonder how they listed the trade on level-2 buy or sell... mmh ..these guys.. ??? ;)
I'm waiting for someone to dump enough for me to pick up another 40.000 shares.. and then I continue to wait.. but will take some profit when it hits 3+ next time... rrrrrrrr
..double amount of stores...mmh eom
I noticed they don't post much on good stocks.. saw from 8 to 16.00 - .30 to 2.70 and 12.oo to 27.oo this seems 2B one of them, people buy and sit back it seems.. ??
If things are so bad then why all the recent grants and Dr./Scientist approvals of this going forward.. ?? I'm pretty sure people who know what they're talking about should be trusted (a little) especially if others are throwing money at this and they rely on review boards in the medical field.. all this bs about time frame makes no sense with all the recent props... from outside sources
..ugH ! Maddness -eom
Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
MONTREAL, Jun 04, 2013 (Marketwired via COMTEX) -- Sunshine Biopharma Inc. (otcqb:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate for breast cancer was found to be effective at killing Pancreatic Cancer Cells in vitro. The study was carried out in the well-established very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing other aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), and Uterine Sarcoma cells (MES-SA/Dx5).
"This brings to four the total number of Aggressive or Multidrug Resistant Cancer types that Adva-27a can destroy. Other chemotherapy drugs are completely ineffective against these cancers," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "This confirms the general effectiveness of Adva-27a against Aggressive or Multidrug Resistant Cancer," he added.
About Pancreatic Cancer Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. According to the American Cancer Society, an estimated 45,220 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013. Approximately 95% of pancreatic tumors are of the adenocarcinoma type, arising within the exocrine component of the pancreas where various digestive enzymes are produced. The remaining 5% arise from the islet cells and are classified as neuroendocrine tumors. The islet cells produce important hormones such as insulin, which regulates the sugar levels in the blood. Both types are very aggressive and respond poorly to standard chemotherapy drugs. In contrast to the downward trend in death rates for most major cancer types, such as lung, colorectal, female breast and prostate, death rates due to pancreatic cancer have been slowly increasing in the U.S. over the past decade. This, together with the lack effective therapy, underscores the need for major new drug development efforts to reverse these trends.
About Sunshine Biopharma Inc. Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
Safe Harbor Forward-Looking Statements To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Anticancer Res. 2012 Oct;32(10):4423-32.
Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells.
Merzouki A, Buschmann MD, Jean M, Young RS, Liao S, Gal S, Li Z, Slilaty SN.
Source
Department of Chemical Engineering, École Polytechnique, Institute of Biomedical Engineering, PO Box 6079, Station Centre-ville, Montréal, Québec, Canada H3C 3A7. abderrazzak.merzouki@polymtl.ca
Abstract
BACKGROUND/AIM:
Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin.
MATERIALS AND METHODS:
Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIa, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats.
RESULTS:
Adva-27a exhibited dose-dependent human topoisomerase IIa inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide.
CONCLUSION:
Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.
PMID: 23060568 [PubMed - indexed for MEDLINE]
..are they allowing the shorts a way out before... ?
mmmnH eom
I've bought a lot more but the board is confusing so I dropped out and I'm guessing many others did 2...
hope so... eom
Even if the US doesn't get onboard will there still be a Euro market ?
http://www.diabetesmine.com/2013/10/inhalable-insulin-and-other-news-from-easd-2013-in-barcelona.html
6 jobs (Connecticut)at Mannkind Corporation matched your search
Mechanic – Fill/Pack
Company: MannKind Corporation 10 days ago Danbury, CT
-----
Supervisor – Warehouse
Company: MannKind Corporation 10 days ago Danbury, CT
-----
Manufacturing Operators
Company: MannKind Corporation 10 days ago Danbury, CT
-----
Specialist, Lyo Mechanic
Company: MannKind Corporation 31 days ago Danbury, CT
-----
Quality Control Associate
Company: MannKind Corporation 51 days ago Danbury, CT
------
QA Manager - CMO/ERP
Company: MannKind Corporation 60 days ago Danbury, CT